COVID-19 Vaccine Market to Reach US$29.98 Billion by 2033 as Variant-Adapted Vaccines, Booster Demand and Next-Generation Platforms Drive 9.8% CAGR

Austin, Texas, April 30, 2026: DataM Intelligence has released its latest analysis on the COVID-19 Vaccine Market, highlighting renewed commercial and public health importance as SARS-CoV-2 continues to evolve and vaccine manufacturers update formulations for circulating variants. According to DataM Intelligence, the Global COVID-19 Vaccine Market reached US$13.43 billion in 2024 and is expected to reach US$29.98 billion by 2033, growing at a CAGR of 9.8% during 2025-2033. The report identifies continued vaccination efforts, government support, variant monitoring, vaccine platform innovation and next-generation vaccine development as key forces shaping market expansion.

Request For Exclusive Sample: https://www.datamintelligence.com/download-sample/covid-19-vaccine-market?kailas

The COVID-19 vaccine market has shifted from emergency pandemic response to a more structured, seasonal, variant-adapted and risk-focused vaccine ecosystem. Initial demand was driven by mass vaccination campaigns, emergency procurement and urgent public health deployment. The next phase is being shaped by booster strategies, elderly and high-risk population protection, updated antigen composition, improved vaccine tolerability, diversified vaccine platforms and the need for resilient manufacturing capacity.

The market remains strategically important because COVID-19 has not disappeared as a healthcare burden. WHO's Technical Advisory Group on COVID-19 Vaccine Composition noted in December 2025 that SARS-CoV-2 continued to circulate globally, with severe disease, post-COVID condition and death still occurring, particularly among individuals aged 65 years and older and those with underlying comorbidities. WHO also recommended monovalent LP.8.1 as the preferred vaccine antigen composition, while stating that previously recommended JN.1-lineage antigens remained suitable alternatives and vaccination should not be delayed while waiting for a specific composition.

Market Momentum Strengthens as COVID-19 Vaccination Becomes Variant-Responsive

The COVID-19 Vaccine Market is gaining long-term structure as vaccine development becomes increasingly linked to variant surveillance and periodic antigen updates. Similar to influenza vaccine planning, manufacturers and regulators are now working within a cycle where circulating variants, immune response data, vaccine effectiveness estimates and clinical evidence influence updated vaccine composition.

WHO's March 2026 statement on data requested for May 2026 deliberations shows how the market is becoming more evidence-driven. The organization stated that its advisory group continues to monitor SARS-CoV-2 genetic and antigenic evolution, immune responses after infection and vaccination, and vaccine performance against circulating variants. WHO also requested clinical and non-clinical immunogenicity data, vaccine effectiveness estimates and manufacturer data to support decisions on future vaccine antigen composition.

This creates a clear commercial need for vaccine manufacturers with rapid update capability, scalable production, regulatory readiness and real-world evidence generation. mRNA platforms remain central because they can be updated quickly against emerging variants. Protein-based vaccines also remain important because they provide a non-mRNA option for eligible populations, while next-generation delivery systems, including intranasal vaccines, may support future differentiation if clinical and regulatory evidence advances.

Updated Vaccines and Risk-Based Recommendations Support Market Stability

The market is also being shaped by updated vaccination guidance. CDC's 2025-2026 vaccination guidance states that COVID-19 vaccination is recommended for people aged 6 months and older based on individual-based decision-making, with the risk-benefit profile most favorable for those at increased risk of severe disease. CDC also notes that people can self-attest to factors that increase their risk for severe COVID-19 and receive vaccination where vaccines are offered.

This guidance supports a more targeted and durable demand base. Adults aged 65 and older, immunocompromised individuals, people with underlying conditions, healthcare workers and residents of congregate settings remain important groups for vaccine access planning. For manufacturers and healthcare distribution networks, this means demand is increasingly tied to seasonal timing, risk-group outreach, provider education, pharmacy availability and payer or public procurement structures.

The commercial value of the market is also tied to operational readiness. COVID-19 vaccines require manufacturing scale, quality controls, regulatory compliance, distribution planning, cold chain management and public health coordination. DataM Intelligence identifies limited manufacturing capacity as a key restraint, noting that vaccine production is highly concentrated and technically demanding, with supply chain risks around raw materials, glass vials, rubber stoppers and other packaging components.

Market Segmentation Analysis

By vaccine type, mRNA vaccines are expected to dominate the market. DataM Intelligence highlights Pfizer-BioNTech and Moderna vaccines as prominent examples of mRNA-based COVID-19 vaccines, with the segment holding a major portion of market share and expected to maintain a significant position during the forecast period. The report also notes that Moderna's investigational next-generation COVID-19 vaccine mRNA-1283 met its primary efficacy endpoint in a Phase 3 trial in June 2024, reinforcing the role of mRNA innovation in market growth.

Protein subunit vaccines remain commercially relevant as an alternative platform. Novavax's Nuvaxovid is positioned as a protein-based, non-mRNA vaccine option in the U.S. for eligible individuals during the 2025-2026 season. This gives healthcare systems and eligible individuals platform diversity at a time when vaccine choice, tolerability, risk communication and updated strain matching are important for market uptake.

Viral vector and inactivated virus vaccines continue to support global vaccine access, especially in markets where legacy manufacturing infrastructure, pricing, distribution requirements or national procurement strategies favor platform diversity. Live attenuated and oral-route candidates remain longer-term areas of interest, particularly if they can support easier administration, improved mucosal immunity or broader deployment models.

By route of administration, intramuscular delivery remains the most established and commercially dominant route. However, intranasal and other next-generation delivery approaches are being studied as manufacturers seek improved immune responses, easier administration and better differentiation. DataM Intelligence notes that NIH initiated a Phase 1 clinical trial in July 2024 for an investigational nasal COVID-19 vaccine designed to improve protection against emerging SARS-CoV-2 variants.

By end-user, hospitals and specialty clinics remain important for vaccination of high-risk populations, immunocompromised individuals and patients requiring physician-guided vaccination decisions. Pharmacies, public health sites and primary care networks also remain critical for broad seasonal vaccine access.

Regional Analysis

North America holds a significant position in the global COVID-19 vaccine market, supported by vaccine awareness, government investment, public health infrastructure, advanced cold chain logistics and the presence of major vaccine manufacturers. DataM Intelligence notes that North America benefits from established healthcare infrastructure and vaccine technology advances, particularly mRNA technology, which support efficient production and distribution.

The United States remains one of the most important markets because of updated vaccine approvals, pharmacy access, public health recommendations, payer pathways and a strong domestic vaccine innovation base. Pfizer and BioNTech's LP.8.1-adapted COMIRNATY received U.S. FDA approval in August 2025 for adults aged 65 and older and individuals aged 5 through 64 with at least one underlying condition that puts them at high risk for severe COVID-19. Pfizer stated that the formulation targets the LP.8.1 sublineage and would begin shipping immediately to support availability in pharmacies, hospitals and clinics.

Europe remains a major market because of ongoing regulatory review, seasonal vaccine planning and public health monitoring. The UK is becoming especially relevant for mRNA manufacturing resilience. Moderna received MHRA approval in February 2026 for its updated Spikevax vaccine targeting LP.8.1 for adults and children aged six months and above. Moderna also stated that the updated vaccine would be supplied from its Innovation and Technology Centre in Harwell, Oxfordshire for the 2026 NHS COVID-19 vaccination campaign.

Asia-Pacific is the fastest-growing region, supported by government procurement, booster demand, healthcare infrastructure expansion and regional vaccine innovation. DataM Intelligence highlights strong government investment and vaccine initiatives across the region, including Australia, Thailand, China, Malaysia, India and other markets. The report also notes that India launched GEMCOVAC-OM, its first mRNA-based booster vaccine designed for Omicron, and that Indian Immunologicals developed a needle-free intranasal booster vaccine with Griffith University in Australia.

Japan, South Korea, China, India and Southeast Asia remain important demand centers due to aging populations, high urban density, public health planning and regional vaccine manufacturing activity. Developed markets such as the UK, Germany, France, Spain, Japan and South Korea will continue to shape demand through booster policy, variant surveillance, regulatory approvals and healthcare-system readiness.

Recent Developments in the Global COVID-19 Vaccine Market

1. Novavax announced Phase 4 head-to-head tolerability results in April 2026. The company stated that Sanofi presented positive results from COMPARE, a double-blind randomized Phase 4 study comparing Novavax's protein-based Nuvaxovid with Moderna's mNEXSPIKE. Novavax reported that Nuvaxovid demonstrated statistically significant lower systemic reactogenicity across all pre-specified endpoints.

2. WHO requested data for May 2026 COVID-19 vaccine antigen composition deliberations. The organization asked vaccine manufacturers and scientific groups to provide variant evolution, immunogenicity, vaccine effectiveness and clinical data to support future vaccine composition decisions, reinforcing the role of continuous evidence generation in the market.

3. Moderna received UK MHRA approval in February 2026 for an updated LP.8.1-targeting Spikevax vaccine. Moderna stated that the vaccine is the first commercially licensed mRNA vaccine to be manufactured in the UK at its Oxfordshire facility and will support the 2026 NHS COVID-19 vaccination campaign.

4. Pfizer and BioNTech received U.S. FDA approval in August 2025 for LP.8.1-adapted COMIRNATY. The companies stated that the 2025-2026 formulation targets LP.8.1 and that preclinical data showed improved immune responses against multiple circulating sublineages compared with JN.1- and KP.2-adapted monovalent vaccines.

5. Novavax received U.S. approval in August 2025 for Nuvaxovid 2025-2026 Formula. Novavax stated that Nuvaxovid was the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season and that Sanofi would lead commercialization efforts.

Competitive Landscape

The COVID-19 vaccine market remains highly competitive, with companies competing across vaccine platform, strain-update speed, regulatory execution, supply reliability, tolerability profile, global distribution, pricing, manufacturing scalability and real-world evidence generation. DataM Intelligence lists major global players including Pfizer/BioNTech, Moderna, Inc., AstraZeneca, Johnson & Johnson, SINOVAC, CanSino Biologics Inc., Novavax, Sanofi/GSK, Beijing Institute of Biological Products Co., Ltd., Serum Institute of India Pvt. Ltd. and Gamaleya Research Institute.

The strongest competitive advantage is expected to come from three capabilities. First, manufacturers need fast antigen-update pathways to respond to SARS-CoV-2 evolution. Second, they need robust regulatory and clinical evidence packages to support approvals across the United States, Europe, Asia-Pacific and other regions. Third, they need reliable manufacturing and distribution systems that can support seasonal demand, targeted booster campaigns and country-specific procurement cycles.

Competition is also shifting toward platform differentiation. mRNA vaccine producers remain well-positioned because of update speed and manufacturing flexibility. Protein-based vaccine producers are gaining relevance where non-mRNA options are valued. Intranasal and next-generation candidates could create future opportunities if clinical data show meaningful benefits in protection, administration or mucosal immune response.

Purchase This Exclusive Sample Report: https://www.datamintelligence.com/buy-now-page?report=covid-19-vaccine-market?kailas

Company Profiles

Pfizer/BioNTech
Pfizer and BioNTech remain central players in the COVID-19 vaccine market through COMIRNATY. Their 2025-2026 LP.8.1-adapted vaccine approval in the U.S. reinforces their ability to update formulations in line with variant guidance and rapidly support seasonal supply. Pfizer stated that 5 billion doses of its COVID-19 vaccine with BioNTech had been distributed globally as of August 2025, demonstrating major scale in manufacturing, distribution and real-world deployment.

Moderna, Inc.
Moderna is a leading mRNA vaccine company with Spikevax and mNEXSPIKE in the COVID-19 vaccine market. Its updated vaccines targeting LP.8.1 received U.S. FDA approval in 2025, while its UK MHRA approval in February 2026 strengthened its European seasonal vaccine position. The company's UK manufacturing capability also supports pandemic preparedness, national supply resilience and rapid access planning for future vaccination campaigns.

Novavax
Novavax is differentiated through its protein-based, non-mRNA COVID-19 vaccine platform. Nuvaxovid's 2025-2026 U.S. approval and the company's Sanofi-led commercialization structure position Novavax in the market as an alternative vaccine-platform provider for eligible individuals. The April 2026 Phase 4 tolerability results also provide a market-relevant evidence signal as vaccine choice, reactogenicity and patient acceptance remain important commercial factors.

Serum Institute of India Pvt. Ltd.
Serum Institute of India remains strategically important because of its scale in vaccine manufacturing and its relevance to global vaccine access. In the COVID-19 vaccine market, large-scale manufacturing partners remain essential for supply security, procurement planning and regional access, particularly in emerging markets where affordability and volume capacity shape vaccination programs. DataM Intelligence includes Serum Institute of India among the major global players in the COVID-19 vaccine market.

Analyst View

The COVID-19 Vaccine Market is no longer defined by emergency procurement alone. The next growth phase is being shaped by variant-adapted vaccine updates, risk-based vaccination policies, platform diversification, post-authorization evidence, manufacturing resilience and public health preparedness.

mRNA vaccines are expected to remain the dominant platform because of update flexibility and established clinical use. However, protein-based vaccines, intranasal candidates and next-generation formulations will remain strategically important as governments and healthcare systems seek broader platform optionality. Markets with aging populations, immunocompromised groups, strong pharmacy networks and seasonal vaccination infrastructure are likely to remain commercially attractive.

The buying intent for this market is linked to regulatory strategy, product lifecycle planning, market access, regional procurement, clinical differentiation and supply chain readiness. Organizations evaluating vaccine portfolio opportunities, public health partnerships, manufacturing investment, variant-update planning or geographic expansion will need detailed intelligence on vaccine type, route, end-user demand, regional policy direction and competitive positioning.

Strategic Outlook

With the market projected to grow from US$13.43 billion in 2024 to US$29.98 billion by 2033, COVID-19 vaccines are expected to remain an important part of global infectious disease prevention, even as demand becomes more seasonal, targeted and evidence-driven. Growth will be supported by ongoing SARS-CoV-2 evolution, updated vaccine composition, elderly and high-risk population needs, booster programs, next-generation vaccine R&D, and strengthened pandemic preparedness infrastructure.

The market's long-term value will depend on speed, evidence and access. Companies that can update formulations efficiently, generate strong clinical and real-world evidence, manage supply reliability and support country-specific vaccination strategies will be better positioned as COVID-19 vaccination becomes a recurring element of public health planning.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.